MetaCap

BioLineRx (BLRX) vs CNS Pharmaceuticals (CNSP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CNS Pharmaceuticals is the larger company by market cap ($5.3 million vs $4.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLRX-56.29%CNSP-34.44%
+3%-28%-59%
Oct 7, 20261 yearNov 20, 2026
BLRX-56.50%CNSP-33.46%
+3%-28%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLRX versus CNSP key metrics
MetricBLRXCNSP
Share price$0.9639$3.56
Market cap$4.80M$5.25M
1-day change-8.20%-12.75%
YTD return-65.20%—
1-year return-70.34%—
5-year return-99.07%—
EPS (TTM)$0.00$-11.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.18M—
Revenue growth (YoY)-95.92%—
Net income (latest FY)$-2.03M$-15.85M
Gross margin80.51%—
Operating margin-871.78%—
Net margin-171.69%—
52-week high$3.95$10.54
52-week low$0.78$1.90
Distance from 52-week high-75.60%-66.22%
Analyst consensusnonenone
Avg. price target upside+2182.39%+180.90%
Average volume23.43K9.30K
Shares outstanding4.98M1.48M
Employees208
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioLineRx

BLRX stock →

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About CNS Pharmaceuticals

CNSP stock →

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

BLRX vs CNSP FAQ

Which is bigger, BioLineRx or CNS Pharmaceuticals?

CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $5.25M compared with $4.80M for BioLineRx (BLRX).

Are BioLineRx and CNS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons